Discovery of 3-((3-amino-<i>1H</i>-indazol-4-yl)ethynyl)-<i>N</i>-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (AKE-72), a potent Pan-BCR-ABL inhibitor including the T315I gatekeeper resistant mutant-Reference-Cited by-同舟云学术

Discovery of 3-((3-amino-1H-indazol-4-yl)ethynyl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (AKE-72), a potent Pan-BCR-ABL inhibitor including the T315I gatekeeper resistant mutant

Published:2023-07-20 Issue:1 Volume:38 Page:
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

El-Damasy Ashraf K.¹²,Kim Hyun Ji¹,Park Jung Woo³,Nam Yunju⁴,Hur Wooyoung⁴,Bang Eun-Kyoung¹,Keum Gyochang¹⁵

Affiliation:

1. Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

2. Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

3. Supercomputing Application Center, Div. of National Supercomputing, Korea Institute of Science and Technology Information, Daejeon, Republic of Korea

4. Medicinal Materials Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

5. Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul, Republic of Korea

Funder

National Research Council of Science & Technology

Korea Institute of Science and Technology

Ministry of Science and ICT

Korea Institute of Science and Technology Information (KISTI) Institutional Program

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2023.2228515

Reference34 articles.

1. Cancer Statistics, 2021

2. The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene

3. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives

4. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

5. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia